Results 81 to 90 of about 8,704 (178)

The novel mineralocorticoid receptor modulator balcinrenone protects against diet-induced cardiac microvascular dysfunction and plasma potassium elevation in mouse models. [PDF]

PLoS One
Wolf MJ, El Moghrabi S, Palacios-Ramirez R, Bamberg K, Bradley LA, Epstein FH, Hartleib-Geschwindner J, Jaisser F.   +7 more
europepmc   +1 more source

Eplerenone lowers maternal blood pressure in a model of leptin-induced preeclampsia, but decreases fetal growth when administered mid-, but not late-, gestation. [PDF]

Am J Physiol Heart Circ Physiol
Mellott E, Moronge D, Cooper G, Backer K, Connor G, Elgazzaz M, Ogbi S, Faulkner JL.   +7 more
europepmc   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration. [PDF]

Drugs Drug Candidates
Al-Horani RA, Goyal N.
europepmc   +1 more source

Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy. [PDF]

Psychopharmacology (Berl)
Wilkinson CS, Bruns N, Pince CL, McGinn MA, Farokhnia M, Leggio L, Vendruscolo LF.   +6 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. [PDF]

Diabetes Obes Metab
Mottl AK, Khunti K, Mathieu C.
europepmc   +1 more source

Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis. [PDF]

BMC Ophthalmol
Park JY, Jang Y, Hahn S.
europepmc   +1 more source

Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024. [PDF]

Front Pharmacol
Ji K, Huang X, Wang F, Zhang L, Zheng Y, Ji L, Ju Y, Zhuang X, Li J.   +8 more
europepmc   +1 more source

Perioperative management of patients with primary aldosteronism: a practical approach for the endocrinologist. [PDF]

Endocr Connect
da Cunha Brito P, de Sousa Lages A, Machado C, Fernandes V.   +3 more
europepmc   +1 more source

Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors. [PDF]

Front Cardiovasc Med
Umanath K, Dwyer JP, Mentz RJ.
europepmc   +1 more source

The Role of Aldosterone in Vascular Permeability in Diabetes. [PDF]

Cells
Aleksiejczuk M, Bielicka N, Bruzgo-Grzybko M, Kalita IS, Olichwier AJ, Mierzejewska P, Stelmaszewska J, Dzieciol J, Chabielska E, Gromotowicz-Poplawska A.   +9 more
europepmc   +1 more source